Low-dose solid oral formulations of cyanocobalamin are manufactured by direct compression only after the active is geometrically diluted in a multi-step trituration sequence because assay variation at 0.025% w/w cannot be controlled by simple mixing. The starting API conforms to the USP Cyanocobalamin monograph with assay on the anhydrous basis between 98.5% and 101.0%, loss on drying not more than 12.0% if the material is hydrated, and residual solvents controlled per ICH Q3C. For a 100 mg tablet core containing 25 µg, the active fraction is 0.025% w/w; for a 1000 µg product, the fraction is 1.0% w/w. Manufacture begins with a 1:9 trituration of API with microcrystalline cellulose screened through a 40 mesh (425 µm) stainless steel sieve to break soft agglomerates. The trituration is then diluted in successive 1:10 steps using a 600 L bin blender filled to 60–70% of rated capacity and rotated at 8–12 rpm for 20 minutes. Direct compression excipients include spray-dried mannitol for brittle fracture, crospovidone 2.0–5.0% w/w as disintegrant, and magnesium stearate 0.5–1.0% w/w added in the final 3 minutes to avoid shear-induced hydrophobization. Tablets are compacted on a rotary press equipped with a force feeder; compression force is maintained between 8 kN and 15 kN for a 7 mm round concave tooling to achieve core hardness of 6–10 kp and friability not more than 1.0% measured under USP <1216>. In-process testing per 21 CFR 211.110 includes stratified blend sampling at discharge, where relative standard deviation of the API assay is held at or below 2.0% before compression. Content uniformity acceptance follows USP <905> with an acceptance value not more than 15.0 for 10 dosage units. Dissolution is conducted under USP <711> using Apparatus 2 at 50 rpm in 900 mL purified water at 37°C ± 0.5°C; the product-specific Q value is set according to the approved monograph. Terminal tablets are film-coated with a light-protective aqueous coating because cyanocobalamin is light-labile, and are packed in PVC/PVDC/aluminium blisters to limit moisture ingress. Published data for this specific direct-compression configuration are limited when the tablet weight falls below 80 mg, so development batches must verify blend homogeneity and ejection force.

What Limits Content Uniformity in Low-Dose Capsule Blending?

Low-dose cyanocobalamin in hard gelatin or HPMC capsules presents the same segregation risk as tablets but differs in fill-volume dynamics through dosator or tamping-pin mechanisms. A size 3 capsule with a 150 mg fill weight carrying 1.0 mg of API gives an active fraction of 0.67% w/w; a 25 µg dose in the same fill weight gives 0.017% w/w, which is below the range where direct fill is normally robust. To avoid dose-dividing losses, API is first triturated 1:9 with pregelatinized starch and passed through a 60 mesh (250 µm) screen. The pre-blend is then diluted with anhydrous lactose or mannitol in a tumbler at 25 rpm for 30 minutes. Dry-fill capsule machines with dosator nozzles demonstrate higher mass variability when the blend contains more than 20% fines below 45 µm, because the nozzle tip compacts the powder bed unevenly and fines adhere to the dosing chamber. Therefore the direct-fill blend is specified with a particle-size distribution where not more than 20% passes through 45 µm and the Carr index is below 25. Encapsulation is conducted at 35–45% RH for HPMC capsules and 45–55% RH for gelatin capsules to avoid shell deformation. Stratified samples are pulled from beginning, middle, and end of the encapsulation run; acceptance is not more than 2.0% RSD for assay and not more than 1.0% RSD for net fill weight. Content uniformity of capsules follows USP <905> with an acceptance value not more than 15.0. Dissolution testing under USP <711> may require the use of a sinker; if formaldehyde crosslinking of gelatin occurs during long-term storage under high humidity, capsule shell dissolution may be retarded and should be evaluated by adding pepsin to the medium as directed in the specific capsule monograph. The terminal product is a red-brown powder in a size 3 hard gelatin or HPMC capsule, packed in a light-resistant container. The API should not be combined with ascorbic acid in this dry blend because trace moisture mobilises the reducing agent and accelerates loss of the cyano ligand on the cobalt center.

Granulation-Endpoint Control for Sachet and Dispersible Powder

Single-dose sachet formulations of Vitamin B12 usually employ dry granulation rather than aqueous wet granulation because the API has a narrow processing window above 40°C in the presence of free water at acidic pH. The API is blended with mannitol, citric acid-free buffering agents, and hydroxypropyl cellulose, then compacted on a roller compactor with roll pressure 40–60 bar and roll gap 2–4 mm; ribbons are milled through a 0.8–1.0 mm screen. Granules are specified with bulk density 0.55–0.65 g/mL and tapped density 0.65–0.75 g/mL, giving a Hausner ratio below 1.25 for reproducible fill. A stick-pack machine fills 1.0–2.0 g of granules per sachet at a target fill weight of 1.5 g; the active content ranges from 25 µg to 1000 µg per sachet. Loss on drying is controlled at not more than 2.0% w/w per USP <731>, and water activity is kept below 0.60 per USP <1112> to prevent microbial proliferation. Content uniformity for single-dose sachets is evaluated by weight variation and assay of individual sachets using the acceptance criteria of USP <905>; for doses below 25 µg, alternative justification under 21 CFR 211.110 may be required. The product is terminally packed in a laminated aluminium foil stick-pack with a seal width of not less than 1.5 mm and subjected to vacuum leak testing according to the packaging validation protocol. Incompatibility: wet granulation with a high-shear mixer at temperatures above 40°C or prolonged contact with citric acid monohydrate shifts the pH below 4.0 and increases free cyanide release; published data for this exact matrix is limited, so forced-degradation studies must be carried out before fixing the granulation endpoint.

Sterile aqueous injection of cyanocobalamin is compounded in a Grade A cleanroom over Grade B background according to EU GMP Annex 1 or ISO 14644-1 class 5. A typical formulation contains 1000 µg/mL cyanocobalamin, 9.0 mg/mL sodium chloride, and 15 mg/mL benzyl alcohol in multi-dose presentations; the solution is buffered to pH 4.5–6.0 with acetate. Water for Injection is sparged with sterile-filtered nitrogen until dissolved oxygen is less than 0.5 mg/L. The API is added under low-speed mixing at 25°C to 35°C, and the solution is filtered through a 0.22 µm PVDF membrane. Vials are amber, Type I borosilicate glass tested per USP <660>; stoppers are halobutyl with low heavy-metal extractables per USP <381>. Filling is performed under a nitrogen overlay to limit oxidative degradation. The solution may be terminally sterilised by moist heat at 121.1°C with an F0 of not less than 8 minutes; if benzyl alcohol or heat-labile complementary vitamins are present, aseptic filtration at 0.22 µm followed by aseptic filling is used instead. Injectable particulate limits follow USP <788> for small-volume parenterals: not more than 6000 particles/container for ≥10 µm and not more than 600 particles/container for ≥25 µm. Visible particle inspection is performed per USP <790>. Osmolality is adjusted to 280–320 mOsm/kg using sodium chloride and verified by USP <785>. The terminal product is a clear red solution in a single-dose or multi-dose vial, with the multi-dose preserved vial limited by benzyl alcohol label warnings in neonates. Incompatibility exists with strong oxidising agents, strong reducing agents, and with solutions containing high concentrations of copper or iron ions; disodium edetate at 0.01–0.05% w/v is added if trace-metal-catalysed degradation is observed during accelerated stability.

When Lyophilized Hydroxocobalamin Requires Isothermal Kinetics Mapping

Lyophilized hydroxocobalamin or cyanocobalamin presentations are selected when aqueous stability is insufficient in combination products or when shipping in high-temperature zones demands a dry cake. The formulation is prepared by dissolving the API in Water for Injection containing 3–5% w/v mannitol as bulk former and, if necessary, 0.01% w/v disodium edetate. The solution is buffered at pH 4.0–6.0 before sterile filtration. Vials are filled to a target dose volume of 0.5–2.0 mL and partially stoppered. Freeze-drying is characterised by differential scanning calorimetry and freeze-drying microscopy to define collapse temperature; a typical conservative cycle freezes the shelf to -40°C ± 2°C and holds for 180 minutes. Primary drying is carried out at a shelf temperature of -20°C to -15°C and chamber pressure of 80–100 mTorr until sublimation front disappearance; secondary drying is performed at 25°C to 35°C under 50 mTorr until residual moisture is not more than 1.0% w/w by USP <921> Method Ic. The final lyocake is red to pink and must be intact; collapsed or melt-back cakes are rejected by visual inspection. Reconstituted solution must be clear and meet the applicable assay acceptance range for the product monograph. Headspace oxygen is replaced with nitrogen, and the moisture limit is confirmed by Karl Fischer titration. Do not use lyophilisation for formulations containing high concentrations of sodium chloride alone as a bulking agent because the collapse temperature is too low and residual water forms a brine phase that accelerates degradation. Published data for lyophilized B12 with crystalline bulking agents such as glycine are limited; development batches require freeze-drying microscopy rather than relying on generic cycles.

Photo-Degradation Thresholds and Vehicle pH in Multi-Dose Oral Drops

Oral drop formulations expose cyanocobalamin to repeated opening, light ingress, and microbiological stress, requiring a preserved aqueous or non-aqueous vehicle. A multi-dose aqueous drop with 0.1–1.0 mg/mL cyanocobalamin is prepared in purified water with sorbitol 25–35% w/w or glycerin 10–20% w/w for viscosity and sweetness. The vehicle is heated to 60–70°C to dissolve methylparaben 0.1% w/v and propylparaben 0.02% w/v, then cooled to 25°C before adding the API solution. pH is adjusted to 4.0–6.0 with citrate or phosphate buffer; pH below 4.0 accelerates cyano ligand loss, and pH above 7.0 promotes alkaline hydrolysis. Disodium edetate 0.02% w/v is included to complex trace metals. The solution is sparged with nitrogen to dissolved oxygen below 0.5 mg/L and filled into amber PET or Type III glass dropper bottles. Photostability is evaluated under ICH Q1B: 1.2 million lux hours visible light and 200 W·h/m² UV; the label claim is verified after exposure. Terminal product is a red liquid with a stamped dropper insert delivering 0.05–0.1 mL per drop; dosing accuracy is tested gravimetrically against the metered dropper specification. Incompatibility: ascorbic acid at concentrations above 1% w/v in the finished drops results in a measurable decline in cyanocobalamin content during 3-month accelerated storage at 40°C ± 2°C / 75% RH ± 5% RH; if combination with vitamin C is required, separate chamber packaging or a non-aqueous vehicle is used. The product should not be stored in low-density polyethylene bottles without a secondary light barrier, as oxygen permeation over 90 days at 40°C reduces assay below the lower acceptance limit in some development batches.